Clinical Trial Detail

NCT ID NCT02726399
Title Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

gastroesophageal junction adenocarcinoma

Therapies

Capecitabine + Cisplatin

Ramucirumab + Trastuzumab

Age Groups: adult

Additional content available in CKB BOOST